TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)

1,380 views

Published on

TapImmune Inc. (OTCBB: TPIV) is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,380
On SlideShare
0
From Embeds
0
Number of Embeds
84
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)

  1. 1. 08/01/11 TapImmune Inc OTC BB:TPIV www.tapimmune.com OTCBB: TPIV
  2. 2. Cautionary Statement Regarding Forward Looking Statements <ul><li>Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company ’s plan of operations and finances, the potential for the Company’s vaccines and proposed clinical trials. </li></ul><ul><li>The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof. </li></ul>08/01/11 TapImmune Inc
  3. 3. 08/01/11 TapImmune Inc “ Development of Immunotherapies for cancer & infectious disease ”
  4. 4. Market for Immunotherapies/Vaccines <ul><li>Fastest growing segment of pharmaceutical market: </li></ul><ul><ul><li>Cancer: </li></ul></ul><ul><ul><ul><li>Projected $6 billion U.S. for cancer vaccines by 2010 with CAGR of 70-100% </li></ul></ul></ul><ul><ul><ul><li>Stimulated by recent approvals of Dendreon ’s Provenge and BMS Yervoy </li></ul></ul></ul><ul><ul><li>Infectious Disease: </li></ul></ul><ul><ul><ul><li>Projected market for 2010 - $11 billion </li></ul></ul></ul><ul><ul><ul><li>Viral pandemics, societal pathogens, bio-defense </li></ul></ul></ul>08/01/11 TapImmune Inc
  5. 5. TAP Technology Platform <ul><li>TAP – Transporters associated with antigen presentation </li></ul><ul><li>Key component in immune recognition pathway </li></ul><ul><li>Stimulates T-cell recognition of antigens and production of cytotoxic T-cells that can infiltrate tumors </li></ul><ul><li>Patents confer broad IP protection </li></ul>08/01/11 TapImmune Inc
  6. 6. TAP is “switched off” in Cancer <ul><li>Many tumors have low or no expression of TAP </li></ul><ul><li>Tumors not recognized as foreign by immune system </li></ul><ul><li>Diminished expression of TAP is associated with disease susceptibility, progression and metastasis </li></ul><ul><li>Vectors re-introducing TAP into tumors boost immunity and reduce tumor burden </li></ul>08/01/11 TapImmune Inc
  7. 7. Need to Augment TAP levels in Infectious Disease <ul><li>Viral infections produce a range of viral peptides that may “overwhelm” TAP system </li></ul><ul><li>Insufficient viral antigens presented to the cellular immune system </li></ul><ul><li>Diminished expression of TAP is associated with disease susceptibility </li></ul><ul><li>Vectors augmenting normal TAP levels boost immunity and greatly improved vaccine efficacy </li></ul>08/01/11 TapImmune Inc
  8. 8. Role of TAP (TAP1/TAP2) in loading peptides to MHC Class I molecules and presentation to Cytotoxic T-cells 08/01/11 TapImmune Inc
  9. 9. 08/01/11 TapImmune Inc TAP treatment restores Immune Recognition in Cancer Tumor cells now visible to the immune system TAP
  10. 10. 08/01/11 TapImmune Inc TAP Enhances Immune Recognition in Infectious Disease Greater number of viral antigens visible to the immune system TAP
  11. 11. Efficacy of TAP vector technology <ul><li>Cancer: </li></ul><ul><ul><li>Mouse models of metastatic melanoma and small cell lung cancer: </li></ul></ul><ul><ul><ul><li>Reduced metastasis </li></ul></ul></ul><ul><ul><ul><li>Higher survival </li></ul></ul></ul><ul><li>Infectious Disease: </li></ul><ul><ul><li>100-1000 fold increase in efficacy of smallpox vaccine in animals. </li></ul></ul>08/01/11 TapImmune Inc
  12. 12. Clinical Development: HER2/neu +ve Breast Cancer Vaccine <ul><li>Combination of TAP + HER2/neu antigens from Mayo Clinic </li></ul><ul><ul><li>applicable to ~ 80% of HER2/neu +ve patients </li></ul></ul><ul><ul><li>IND for Phase I studies approved </li></ul></ul><ul><li>Current therapy: </li></ul><ul><ul><li>Trastuzumab (Herceptin) over $5billion in annual sales </li></ul></ul><ul><ul><li>applicable to ~ 30% of HER2/neu +ve patients </li></ul></ul>08/01/11 TapImmune Inc
  13. 13. Research Smallpox/Biodefense Vaccines <ul><li>TAP improved potency of smallpox vaccine by 100-1000 fold </li></ul><ul><li>TAP + peptide antigens licensed from Mayo Clinic </li></ul><ul><ul><li>Broader patient population; cheaper, longer shelf-life </li></ul></ul><ul><li>“ Animal Efficacy Rule” FDA pathway (24-36 months to potential stockpiling) </li></ul><ul><li>Potential for TAP to be stockpiled for variety of emerging bio-threats, e.g. Dengue </li></ul>08/01/11 TapImmune Inc
  14. 14. Leverage of Collaborations <ul><li>Crucell NV </li></ul><ul><ul><li>TAP manufacturing </li></ul></ul><ul><li>Research Collaboration with Aeras Global TB Vaccine Foundation </li></ul><ul><ul><li>TB antigens (Phase II clinical) + TAP </li></ul></ul><ul><li>License Option Agreements with Mayo Clinic: </li></ul><ul><ul><li>HER2/neu +ve breast cancer antigen technology </li></ul></ul><ul><ul><li>Smallpox virus antigen technology </li></ul></ul>08/01/11 TapImmune Inc
  15. 15. Advisors & R&D Team <ul><ul><li>Mac Cheever (Corixa; Fred Hutchinson Cancer Center) </li></ul></ul><ul><ul><li>Mark Reddish (Biomira; ID Biomedical) </li></ul></ul><ul><ul><li>Keith Knutson (Mayo Clinic) </li></ul></ul><ul><ul><li>Greg Poland (Mayo Clinic) </li></ul></ul><ul><ul><li>Lynn Depippo (Sherbrook Capital Management) </li></ul></ul>08/01/11 TapImmune Inc
  16. 16. 08/01/11 TapImmune Inc <ul><li>Technology discovery at University of British Columbia </li></ul><ul><li>Founded as a public corporation on OTCBB (TPIV) </li></ul><ul><li>Based in Seattle, WA </li></ul><ul><li>~ 47 million shares outstanding (22 million in float) </li></ul><ul><li>Management & Affiliates ~ 30% </li></ul>Corporate Profile www.tapimmune.com
  17. 17. Our Vision for TAP <ul><li>Leading immunotherapy in the fight against cancer: </li></ul><ul><ul><li>Multiple metastatic cancers </li></ul></ul><ul><ul><li>Multiple combination products </li></ul></ul><ul><ul><li>Early stage prophylactic use </li></ul></ul><ul><li>Stockpiled for biodefense threats and viral pandemics: </li></ul><ul><ul><li>Variety of infectious diseases </li></ul></ul><ul><ul><li>Emerging bio-terrorist threats </li></ul></ul><ul><ul><li>Making other vaccines more effective </li></ul></ul>08/01/11 TapImmune Inc
  18. 18. Looking for Investors that Share our Vision Why Invest in TPIV now? <ul><li>Breakthrough technology </li></ul><ul><li>Strong product pipeline </li></ul><ul><li>World-class team and collaborators </li></ul><ul><li>Risk diversification – cancer & infectious disease </li></ul><ul><li>Compelling preclinical data </li></ul><ul><li>Start of clinical programs </li></ul><ul><li>Undervalued and poised for significant growth </li></ul>08/01/11 TapImmune Inc

×